Drug Trial Radar · NCT05243680
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
641
Actual
Start
Mar 1, 2022
Primary completion
May 19, 2025
Study completion May 19, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Feb 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.
Conditions
- Asthma
Interventions
GSK3511294 (Depemokimab)Biological
GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs)Time frame: Up to Week 56
- Number of Participants With Worst Case Post-Baseline Positive Anti-GSK3511294 Antibodies (ADA)Time frame: Up to Week 52
- Number of Participants With Worst Case Post-Baseline Positive Neutralizing AntibodiesTime frame: Up to Week 52
Locations
137 sites in 14 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Lancaster, California
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Lafayette, Colorado
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Loxahatchee Groves, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Savannah, Georgia
GSK Investigational Site
Normal, Illinois
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Ypsilanti, Michigan
GSK Investigational Site
Northfield, New Jersey
GSK Investigational Site
Toms River, New Jersey
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Gastonia, North Carolina
GSK Investigational Site
Huntersville, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
DuBois, Pennsylvania
GSK Investigational Site
Allen, Texas
GSK Investigational Site
Boerne, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Kerrville, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Bellingham, Washington
GSK Investigational Site
Coffs Harbour, New South Wales, Australia
GSK Investigational Site
South Brisbane, Queensland, Australia
GSK Investigational Site
Sherwood Park, Alberta, Canada
GSK Investigational Site
Kamloops, British Columbia, Canada
GSK Investigational Site
Ajax, Ontario, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Changchun, China
GSK Investigational Site
Changchun, China
GSK Investigational Site
Chengdu, China
GSK Investigational Site
Guangzhou, China
GSK Investigational Site
Guangzhou, China
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.